Anti-EGFR Antibody Formulation Stability via Salt-Free Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional liquid formulations of anti-EGFR antibodies face stability issues due to protein aggregation and denaturation, leading to particle formation and turbidity, which complicates administration and reduces stability, even after filtration, and often include sodium chloride that may not be compatible for optimal protein formulations.
Innovation Solution
A pharmaceutical formulation comprising the anti-EGFR antibody GC1118A, sodium acetate anhydrous, and polysorbate 80, without sodium chloride, is developed to maintain stability and prevent aggregation, with specific concentrations and pH ranges optimized to minimize turbidity and particle formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a liquid formulation comprising an anti-EGFR antibody is stored, then the antibody may be administered therapeutically, but protein multimers may be formed due to aggregation and deamination reactions may occur due to proteolytic reactions
Solution Approach 1:
The patent applies parameter changes by optimizing the pH range (5.0-7.0) and selecting specific stabilizer concentrations (0.1-5% w/v) to prevent antibody aggregation and deamination. This chemical parameter optimization resolves the contradiction by creating a formulation environment that maintains antibody stability during storage while enabling therapeutic administration.
Solution Approach 2:
The patent introduces stabilizers (such as sugars, amino acids, or polymers) as intermediary substances that mediate between the antibody and the storage environment. These stabilizers prevent direct harmful interactions between the antibody and stressors like elevated temperature or shear stress, thereby preventing aggregation and denaturation while maintaining therapeutic utility.
2Reliability
If filtration process is applied to prevent aggregation, then particle formation may be reduced, but the administration method becomes complicated and particle formation may continue after filtration
Solution Approach 1:
The patent applies preliminary action by incorporating stabilizers into the formulation before storage, which proactively prevent aggregation and particle formation during storage conditions. This prevents the need for post-storage filtration steps, simplifying the administration method while maintaining reliability in preventing aggregation.
Solution Approach 2:
The patent converts the potential harm of aggregation into a benefit by using stabilizers that, under controlled conditions, maintain antibody solubility and prevent precipitation. The stabilizers that could potentially increase viscosity are optimized at concentrations that prevent aggregation without compromising administerability, thus converting a potential disadvantage into a protective mechanism.
3Object-affected harmful factors
If sodium chloride is added as isotonization agent, then pain reaction may be reduced, but compatibility with protein therapeutics must be verified and may not optimize stability
Solution Approach 1:
The patent applies the taking out principle by removing sodium chloride from the formulation and replacing it with alternative isotonization agents such as sugars or amino acids. This extraction of NaCl eliminates potential compatibility issues and stability problems associated with salt-protein interactions, while still achieving the desired osmotic balance to reduce pain reactions upon administration.
Solution Approach 2:
The patent employs composite materials by combining the antibody with stabilizers and alternative isotonization agents in a synergistic formulation system. This composite approach creates a multi-component system where each ingredient contributes specific functions: stabilizers prevent aggregation, alternative tonicity agents reduce pain without compromising stability, and the combination achieves both therapeutic efficacy and patient comfort.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention provides a pharmaceutical formulation comprising an anti- epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.